Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bicanorm and DLI in Relapsed AML
NCT04321161Phase 1Completed
- Sponsor
- University of Freiburg
- Start
- Feb 2020
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sodium bicarbonate in acute myeloid leukemia (AML), sponsored by University of Freiburg. Primary endpoints: T cell glycolytic activity at 2 months, T cell respiratory activity at 2 months and 1 more. Started Feb 2020; status: completed.
02
Drugs
sodium bicarbonate
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04321161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04321161.